KDR2-2

N/A

Report date: 2022/01/17 12:14:22
NME

Base Information

Drug NameKDR2-2
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsPlatelet-derived growth factor receptor beta inhibitors
TargetsVascular endothelial growth factor receptor 2Platelet-derived growth factor receptor beta
Therapy Area/IndicationsNeovascularization, PathologicGlaucoma, NeovascularCorneal Neovascularization
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Huiborui Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSun Yat-Sen UniversityGuangzhou Huiborui Biomedical Technology Co Ltd
Inactive CompaniesZhongshan Ophthalmic Center Sun Yat-Sen University
Active IndicationsNeovascularization, PathologicGlaucoma, NeovascularCorneal Neovascularization
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A